Helsinn Therapeutics, Inc. has released an important announcement about the discontinuation of distribution of TRUSELTIQ® (infigratinib) capsules as of the first quarter of 2023. It is important to note that this discontinuation is not for safety or efficacy reasons but is based on difficulties in recruiting and enrolling study subjects for the required confirmatory clinical trial.
To sign up for our newsletter or print publications, please enter your contact information below.
